{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-106936","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2022-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.931267+00:00","generated_at":"2026-06-23T04:44:50.741621+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Replimune secures $200M non-dilutive debt facility from Hercules Capital","bullets":["$200M term loan; $30M funded at closing, $30M available by Sep 30, 2023.","Up to $115M available upon clinical/regulatory/commercial milestones; $25M subject to Hercules consent.","Interest: floating cash rate (greater of 7.25% or Prime+1.75% capped at 7.25%) plus 1.50% PIK.","At least 48 months interest-only, extendable to 60 months on milestone achievement; matures Oct 2027.","Proceeds extend cash runway into 2025 ahead of CERPASS/IGNYTE trial catalysts and commercial prep."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-106936","json":"https://secwatch.observer/filing/0001104659-22-106936.json","markdown":"https://secwatch.observer/filing/0001104659-22-106936.md","text":"https://secwatch.observer/filing/0001104659-22-106936.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465922106936/0001104659-22-106936-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465922106936/tm2227789d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:44:50.741621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}